Advanced BioNutrition and Chr. Hansen Sign Agreement for Probiotic Delivery System
The technology agreement focuses on adapting ABN’s patented technologies to stabilize probiotics in defined applications, and, as research shows, may be beneficial in a wide variety of intestinal disorders.
Mar 16 2012 --- Advanced BioNutrition Corp. (ABN), a leader in providing science-based solutions to improve health and nutrition, has announced the signing of a technology agreement with Chr. Hansen A/S, a worldwide leader in the manufacture and marketing of probiotics headquartered in Copenhagen. The technology agreement focuses on adapting ABN’s patented technologies to stabilize probiotics in defined applications, and, as research shows, may be beneficial in a wide variety of intestinal disorders.
This is the first technology agreement Advanced BioNutrition has signed with a food nutrients company. Terms of the agreement were not disclosed.
“We are pleased to have this opportunity to work with Chr. Hansen,” said Larry Loehr, director of ABN Business Development. “We look forward to a successful completion of this technology agreement with Chr. Hansen and additional work with this great company.”
“Chr. Hansen is a global supplier of bioscience-based ingredients to the food, health and animal feed industries, said Lasse Nagell, vice president, Sales & Marketing Human Health & Nutrition Division, for Chr. Hansen. “We produce cultures and dairy enzymes, probiotics and natural colors. Our business is built on our product innovation and applications, production processes, long-term customer relationships and intellectual property. We believe ABN’s technologies will help us stabilize and deliver probiotics and other nutrients in a number of applications.”
ABN takes a proactive approach to resolving product formulation and manufacturing process challenges for customers. Customizing distinctive technologies in the pursuit of solving specific problems is done in collaboration with customers such as Chr. Hansen. ABN research scientists work along side Chr. Hansen research and development teams, adapting ABN’s portfolio of innovative technologies to customize a protection, stabilization, and/or delivery solution that will help the customer capture more value, with products and processes that can lead to enhanced or improved human health.
ABN’s patented technologies capture the active ingredient, acting to stabilize, protect, and efficiently deliver the product to its final target site of action. In addition to the delivery of probiotics, omega-3 oils, vitamins, carotenoids, enzymes, and amino acids for human nutrition and industrial applications it has proven capable of targeted feeding in aquatic applications ranging from fish to shrimp. The ABN technology allows commercial fish farmers to deliver vaccines in effective and efficient new ways to induce an effective immune response in salmonid species.
